UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 4)* La Jolla Pharmaceutical Company - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $ .01 per Share - -------------------------------------------------------------------------------- (Title of Class of Securities) 503459109 (CUSIP Number) Jose M. de Lasa, 100 Abbott Park Road Abbott Park, Illinois 60064-6049; Phone 847 937 8905 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 22, 2001 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ _ ]. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 503459109 - -------------------------------------------------------------------------------- 1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Abbott Laboratories IRS Identification No. 36-0698440 - -------------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [_] - -------------------------------------------------------------------------------- 3) SEC USE ONLY - -------------------------------------------------------------------------------- 4) SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_] - -------------------------------------------------------------------------------- 6) CITIZENSHIP OR PLACE OF ORGANIZATION Illinois - -------------------------------------------------------------------------------- NUMBER OF (7) SOLE VOTING POWER SHARES 2,603,104 BENEFICIALLY ------------------------------------------------------- OWNED BY (8) SHARED VOTING POWER EACH 0 REPORTING ------------------------------------------------------- PERSON WITH (9) SOLE DISPOSITIVE POWER 2,603,104 ------------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 - -------------------------------------------------------------------------------- 11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,603,104 - -------------------------------------------------------------------------------- 12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] - -------------------------------------------------------------------------------- 13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 7.4% (see Item 5 below) - -------------------------------------------------------------------------------- 14) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - -------------------------------------------------------------------------------- Page 2 of 4 pages
The following information amends and supplements the Schedule 13D filed on January 2, 1997 (the "Schedule 13D"), the First Amendment to the Schedule 13D filed on September 26, 1997, the Second Amendment to the Schedule 13D filed on December 17, 1998, and the Third Amendment to the Schedule 13D filed on April 17, 2001 (the "Third Amendment"). Capitalized terms used herein but not otherwise defined shall have the meanings described in the Schedule 13D. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER (a) As of May 22, 2001, Abbott was the beneficial owner of 2,603,104 shares of Common Stock (the "Shares"), representing approximately 7.4% of the outstanding shares of the Common Stock. (b) Abbott has sole power to vote or to direct the vote and the sole power to dispose or to direct the disposition of the Shares. (c) In addition to the sales described in Item 5 of the Third Amendment, Abbott has effected the following open market sales of the Common Stock in the past 60 days: Date Number of Shares Sold Average Price Per Share ---- --------------------- ----------------------- April 19, 2001 25,000 $5.20 April 20, 2001 7,500 $5.20 April 30, 2001 30,000 $5.25 May 1, 2001 5,000 $5.20 May 2, 2001 5,000 $5.40 May 7, 2001 5,000 $5.61 May 8, 2001 10,000 $5.65 May 11, 2001 10,000 $5.60 May 14, 2001 10,000 $5.7975 May 15, 2001 12,500 $5.9100 May 16, 2001 32,500 $6.2785 May 17, 2001 170,000 $7.291765 May 18, 2001 5,000 $7.26 May 21, 2001 9,000 $7.5733 May 22, 2001 10,000 $7.5100 (d) No one other than Abbott is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from a sale of, the Shares. (e) Not applicable. Page 3 of 4 pages
SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Abbott Laboratories DATED: May 23, 2001 By: /s/ Thomas C. Freyman ------------------------------------- Thomas C. Freyman, Senior Vice President, Finance and Chief Financial Officer Page 4 of 4 pages